Chemomab Therapeutics (CMMB) Other financing activities (2020 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Other financing activities came in at -$14.2 million in Q4 2023, down 17365.85% YoY from N/an in Q4 2022, and down 454.75% on a QoQ basis from $4.0 million in Q3 2023.
Chemomab Therapeutics (CMMB) Other financing activities (2020 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has 4 years of Other financing activities data on file, last reported at -$14.2 million in Q4 2023.
- Quarterly Other financing activities fell 17365.85% year-over-year to -$14.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$10.0 million (down 7125.17% YoY) and the FY2025 annual result came in at $12000.0, changed N/A from the prior year.
- Other financing activities slipped to -$14.2 million in Q4 2023, from $4.0 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $4.0 million in Q3 2023 to a low of -$14.2 million in Q4 2023.
- A 4-year average of -$876400.0 and a median of $103500.0 in 2020 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 10133.33% in 2023, down 17365.85% in 2023.
- Tracing CMMB's Other financing activities over 4 years: stood at $563000.0 in 2020, then sank by 529.31% to -$2.4 million in 2021, then surged by 103.39% to $82000.0 in 2022, then sank by 17365.85% to -$14.2 million in 2023.
- The last three Other financing activities figures came in at -$14.2 million (Q4 2023), $4.0 million (Q3 2023), and $82000.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -14.16 Mn |
| Dec 31, 2023 | -14.16 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Dec 31, 2022 | 82,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Dec 31, 2021 | -2.42 Mn |
| Dec 31, 2021 | -2.42 Mn |
| Mar 31, 2021 | 2.43 Mn |
| Mar 31, 2021 | 2.43 Mn |
| Dec 31, 2020 | 563,000.00 |
| Dec 31, 2020 | 563,000.00 |
| Sep 30, 2020 | 562,000.00 |
| Sep 30, 2020 | 562,000.00 |
| Jun 30, 2020 | 125,000.00 |
| Jun 30, 2020 | 125,000.00 |